Drug Patent Watch

JANUARY 8, 2022

Annual Drug Patent Expirations for GIVLAARI Givlaari is a drug marketed by Alnylam Pharms Inc and is included in one NDA. There are twelve patents protecting this drug. This drug…. The post New patent expiration for Alnylam Pharms drug GIVLAARI appeared first on DrugPatentWatch - Make Better Decisions.

Drugs 52

Drugs Marketing 52

Cloudbyz

JANUARY 8, 2022

The success of clinical trials depends on multiple factors. Only a handful of those factors however, are irreplaceable. Factors being irreplaceable means that no amount of alternative resources can make the trial successful. Patient engagement is one such irreplaceable factor. Engaging patients is necessary throughout the entire clinical trial. It begins with recruitment and ends with the study’s conclusion.

Clinical Trials 52

Clinical Trials Clinical Trials Trials Research 52

BioTech 365

JANUARY 8, 2022

Orange County CA Auto Injury Chiropractor – Whiplash/Concussion Treatment Update Orange County CA Auto Injury Chiropractor – Whiplash/Concussion Treatment Update Dr.

52

52

Drug Patent Watch

JANUARY 8, 2022

This chart shows the drugs with the most supplementary protection certificates (SPCs). SPCs are used in European Union and select others to encourage pharmaceutical innovation by compensating for the long…. The post Which drugs have the most supplementary protection certificates? appeared first on DrugPatentWatch - Make Better Decisions.

Drugs 98

Drugs 98

Advertisement

Planning on running clinical trials in Japan? How can you reliably supply these studies? Discover Catalent’s clinical supply packaging facility in Shiga, Japan. Strategically located between Tokyo and Osaka, and one of largest in Japan, this 6,000 square meter facility offers comprehensive services including primary and secondary clinical packaging and labelling, comparator sourcing, cold chain storage, local and global distribution, local language support and white glove service to support stud

Clinical Research

BioTech 365

JANUARY 8, 2022

COVAXIN™ (BBV152) Booster Dose Study Demonstrates Robust Immune Responses and Long-Term Safety COVAXIN™ (BBV152) Booster Dose Study Demonstrates Robust Immune Responses and Long-Term Safety Participants receiving a booster dose six months after second dose of COVAXIN™ saw significant increase (>10-fold … Continue reading →

Immune Response 40

Immune Response 40

BioTech 365

JANUARY 8, 2022

Core One Labs Now Also Working to Biosynthesize DMT and Receives License Core One Labs Now Also Working to Biosynthesize DMT and Receives License VANCOUVER, British Columbia, Jan. 08, 2022 (GLOBE NEWSWIRE) — Core One Labs Inc.

Licensing 40

Licensing Licensing 40